• Aussie shares drop around 1pc at lunch as Middle East conflict weighs
  • Oil stocks rise with crude prices up 5% after Biden’s comments
  • ANZ Bank falls 1pc amid $50 million class action settlement

 

Aussie shares tumbled at the start of trade and are down by 0.9% at noon as the escalating conflict in the Middle East weighs on the market.

Concerns are rising that Israel might target Iranian oil assets in retaliation, leading to losses across the index.

Oil stocks are seeing gains as crude prices jumped by 5%. This follows President Biden’s suggestion that the US might consider a strike on Iranian oil assets in response to a recent missile attack on Israel.

“First of all, we don’t ‘allow’ Israel, we advise Israel. And there is nothing going to happen today,” Biden said.

Experts say a major attack on Iran’s oil facilities could reduce supply by 1.5 million barrels per day, while smaller strikes could take out between 300,000 and 450,000 barrels.

Separately, Woodside (ASX:WDS) reported a fatal incident at its Beaumont Clean Ammonia facility in Texas. Its shares, however, rose 2% on the back of oil sentiment.

But gains in energy stocks were offset by losses in iron ore stocks today as iron ore futures in Singapore retreated by 1%. BHP (ASX:BHP)Rio Tinto (ASX:RIO) and Fortescue (ASX:FMG) were all down by over 2%.

Still in the large caps space, ANZ Bank (ASX:ANZ) fell 1% after OnePath Custodians (OPC), along with Zurich Australia and ANZ reached a $50 million settlement in a class action lawsuit with certain OPC members. The lawsuit claimed these members didn’t receive fair interest rates on their investments before January 2020.

Elsewhere, fund manager Regal Partners (ASX:RPL) has agreed to allow Platinum Asset Management (ASX:PTM) to peek into its books, enabling Platinum to potentially make a better acquisition offer. While Regal initially rejected Platinum’s proposal, this due diligence could result in a more attractive offer price.

Source: Market Index

 

NOT THE ASX

Overnight, Wall Street fell across the board, with the S&P500 down by 0.17%, the blue chips Dow Jones by 0.44% and the tech heavy Nasdaq by 0.04%.

President Biden spooked markets when he suggested the US might be considering a potential strike on Iranian oil assets in response to a recent missile attack on Israel.

Crude prices jumped by another 5% on his comments, bringing this week’s total rise to 9%, and energy stocks on Wall Street outperformed the broader market.

Wall Street’s VIX index, sometimes called the fear index, jumped 8%.

“The VIX is signalling that we are still in the midst of the ‘iffy October’ period, but we ultimately expect investors to buy this dip,” said Fundstrat’s Thomas Lee.

But with limited market-moving data, all eyes are now on Friday’s US payrolls report, which will influence the Fed Reserve’s next decision on interest rates.

“We continue to expect more aggressive easing as the Fed confronts a rapidly softening labour market,” said Andrew Hollenhors at Citigroup.

To stocks, Nvidia rose by 3.37% on no specific news, taking its market cap back above the US$3 trillion mark.

Tesla shares keep falling, down by another 3.4% last night, after reporting disappointing delivery numbers on Wednesday.

Most retailers, like Walmart, Amazon and Target were sold off as the the US East and Gulf coast ports strike hits day three.

AND … the ongoing chaos caused by the US dockworkers strike could cost the US economy up to US$4.5 billion daily, say experts.

An update to this plotline, though: US port workers and operators have reportedly in the past few hours, according to Reuters, tentatively agreed to reach a deal to end the strike.

 

ASX SMALL CAP WINNERS

Here are the best performing ASX small cap stocks for October 4 [intraday]:

Swipe or scroll to reveal full table. Click headings to sort:

Wordpress Table Plugin

Control Bionics (ASX:CBL) is faring well today on the back of some good news. The company has reported a significant improvement in NDIS approvals alongside the launch of a long-term leasing program for its Trilogy system. Trilogy is designed to help individuals with neurodegenerative conditions gain quicker access to vital communication technology.

The company has received approvals from the NDIS totalling close to $400k in the past eight weeks. There has been a growing momentum in NDIS approval process in recent times, noted Control Bionics, adding that its new long-term leasing program for Trilogy has been well received.

Island Pharmaceuticals (ASX:ILA) meanwhile is still trading nicely off the back of its news from yesterday.

The company announced it has successfully dosed all subjects in the Phase 2a part of its ISLA-101 clinical trial for dengue fever.

This trial, called PROTECT, includes both a preventative (Phase 2a) and a therapeutic (Phase 2b) approach. Starting today, subjects will be exposed to an attenuated strain of the dengue virus, and results from Phase 2a are expected by the end of 2024. The Phase 2b trial is set to begin in January 2025.

As part of this, ILA is raising $3.5 million in a two-tranche placement to achieve its “near term inflexion points”. The raising was struck at 7 cents per share, a 12% discount, with one attached options for every share issue at the same price. Half of the oppies expire within 12 months of issue; the other half within 24 months. Subject to shareholder approval, the placement was supported by well-known biotech names including Dr Daniel Tillett, the head of cancer drug repurposer Race Oncology (ASX:RAC).

 

ASX SMALL CAP LOSERS

Here are the most-worst performing ASX small cap stocks for October 4 [intraday]:

Swipe or scroll to reveal full table. Click headings to sort:

Wordpress Table Plugin

 

IN CASE YOU MISSED IT

AdAlta (ASX:1AD) has received its Research and Development Tax Incentive (RDTI) for FY2024 of $1.77m, enabling full repayment of the balance of the company’s Treasury Corporation of Victoria loan facility of $1.4m.

That leaves a tidy $0.37m left to boost the company’s balance sheet.

The biotech company targets untreated diseases using the i-body: a unique drug discovery platform.

“I personally want to thank the Victorian Government for granting AdAlta this now repaid loan, which came our way via the Government’s R&D Cash Flow Loan Initiative,” CEO and MD Dr Tim Oldham said.

“This debt facility added significant flexibility to our ongoing funding plans for AdAlta’s research and development program and reduced our reliance on equity capital.”

 

At Stockhead, we tell it like it is. While AdAlta is a Stockhead advertiser, it did not sponsor this article.